- Home
- EXE vs WAT Comparison
EXE vs WAT Comparison
Compare EXE & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXE
- WAT
- Stock Information
- Founded
- EXE 1989
- WAT 1958
- Country
- EXE United States
- WAT United States
- Employees
- EXE N/A
- WAT N/A
- Industry
- EXE
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- EXE
- WAT Industrials
- Exchange
- EXE NYSE
- WAT Nasdaq
- Market Cap
- EXE 22.8B
- WAT 22.5B
- IPO Year
- EXE 1993
- WAT 1995
- Fundamental
- Price
- EXE $94.50
- WAT $360.36
- Analyst Decision
- EXE Strong Buy
- WAT Hold
- Analyst Count
- EXE 5
- WAT 12
- Target Price
- EXE $113.60
- WAT $374.75
- AVG Volume (30 Days)
- EXE 2.6M
- WAT 514.6K
- Earning Date
- EXE 02-07-2025
- WAT 02-04-2025
- Dividend Yield
- EXE 2.43%
- WAT N/A
- EPS Growth
- EXE N/A
- WAT N/A
- EPS
- EXE 1.89
- WAT 10.48
- Revenue
- EXE $3,291,000,000.00
- WAT $2,905,147,000.00
- Revenue This Year
- EXE N/A
- WAT $0.53
- Revenue Next Year
- EXE N/A
- WAT $5.59
- P/E Ratio
- EXE $49.95
- WAT $34.40
- Revenue Growth
- EXE N/A
- WAT N/A
- 52 Week Low
- EXE $69.12
- WAT $279.24
- 52 Week High
- EXE $101.27
- WAT $397.02
- Technical
- Relative Strength Index (RSI)
- EXE N/A
- WAT 39.23
- Support Level
- EXE N/A
- WAT $380.60
- Resistance Level
- EXE N/A
- WAT $379.00
- Average True Range (ATR)
- EXE 0.00
- WAT 9.35
- MACD
- EXE 0.00
- WAT -3.33
- Stochastic Oscillator
- EXE 0.00
- WAT 0.95
About EXE EXPAND ENERGY CORPORATION
Expand Energy Corp independent natural gas producer in the United States. It is fueling a more affordable, reliable, and lower-carbon future. The group focused on developing abundant natural gas, oil, and gas liquids to expand energy access.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2023, Waters generated 57% from biopharmaceutical customers, 31% from industrial clients, and 12% from academic/government institutions.